Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bladder cancer.

Eric S Gwynn1, Peter E Clark

  • 1Department of Urology, Wake Forest University Health Sciences, Winston-Salem, North Carolina 27157, USA.

Current Opinion in Oncology
|March 23, 2006
PubMed
Summary
This summary is machine-generated.

This review covers recent advancements in bladder cancer management. Key findings include Bacille Calmette-Guerin (BCG) efficacy for carcinoma in situ and evolving chemotherapy roles for advanced disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.

European urology·2026
Same author

Racial and socioeconomic disparities from time of diagnosis to treatment for small renal masses.

BJUI compass·2026
Same author

Protocol-driven same day discharge for robotic radical prostatectomy.

Urologic oncology·2025
Same author

Diagnostic yield of upper tract imaging performed for hematuria screening: Results from a national, privately-insured cohort.

Urologic oncology·2024
Same author

Change in prostate tissue gene expression following finasteride or doxazosin administration in the medical therapy for prostatic symptoms (MTOPS) study.

Scientific reports·2024
Same author

Reply by Authors.

Urology practice·2024
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Uro-oncology
  • Cancer Diagnosis and Treatment

Background:

  • Bladder cancer diagnosis relies on cystoscopy, with ongoing research into improved urinary markers and fluorescence endoscopy.
  • Management strategies vary by stage, from superficial tumors to metastatic disease.

Purpose of the Study:

  • To review the diagnosis and management of bladder cancer across all stages.
  • To highlight recent developments in bladder cancer care over the past year.

Main Methods:

  • Review of current literature and recent developments in bladder cancer diagnosis and treatment.
  • Emphasis on staging, from superficial to metastatic disease.

Main Results:

  • Bacille Calmette-Guerin (BCG) is the most effective therapy for carcinoma in situ, with maintenance therapy recommended.

Related Experiment Videos

  • Muscle-invasive bladder cancer management in the US focuses on radical cystectomy with pelvic lymphadenectomy.
  • Research areas include bladder preservation, laparoscopic approaches, quality of life with urinary diversion, and optimal lymphadenectomy.
  • The role of combination chemotherapy for advanced bladder cancer is evolving, with unanswered questions regarding neoadjuvant vs. adjuvant therapy and optimal regimens.

    • Conclusions:

    • Superficial bladder cancer management involves transurethral resection and perioperative intravesical chemotherapy.
    • Risk stratification for high-risk superficial bladder cancer remains a challenge.
    • Continued research aims to enhance diagnostic tools and treatment strategies for all stages of bladder cancer.